Microsatellite instability testing in colorectal carcinoma: Choice of markers affects sensitivity of detection of mismatch repair-deficient tumors

被引:68
作者
Hatch, SB
Lightfoot, HM
Garwacki, CP
Moore, DT
Calvo, BF
Woosley, JT
Sciarrotta, J
Funkhouser, WK
Farber, RA
机构
[1] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA
[4] Univ N Carolina, Dept Surg, Chapel Hill, NC 27599 USA
[5] Univ N Carolina, Dept Biostat, Chapel Hill, NC 27599 USA
[6] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
关键词
D O I
10.1158/1078-0432.CCR-04-0234
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Microsatellite instability (MSI) is found in 10% to 15% of sporadic colorectal tumors and is usually caused by defects in DNA mismatch repair (MMR). In 1997, a panel of microsateltite markers including mononucleotide and dinucleotide repeats was recommended by a National Cancer Institute workshop on MSI. We investigated the relationship between instability of these markers and MMR protein expression in a cohort of sporadic colorectal cancer patients. Experimental Design: Paraffin sections of normal and tumor tissue from 262 colorectal cancer patients were examined for MSI status by PCR amplification and for MMR protein expression using antibodies against hMLH1, hPMS2, hMSH2, and hMSH6. Results: Twenty-six (10%) of the patients studied had tumors with a high level of MSI (MSI-H). The frequencies of NISI were the same in African-American and Caucasian patients. Each of the MSI-H tumors had mutations in both mononucleotide and dinucleotide repeats and had loss of MMR protein expression, as did two tumors that had low levels of MSI (MSI-L). These two MSI-L tumors exhibited mutations in mononucleotide repeats only, whereas eight of the other nine MSI-L tumors had mutations in just a single dinucleotide repeat. There was not a statistically significant difference in outcomes between patients whose tumors were MMR-positive or MMR-negative, although there was a slight trend toward improved survival among those with MMR-deficient tumors. Conclusions: The choice of microsatellite markers is important for MSI testing. Examination of mononucleotide repeats is sufficient for detection of tumors with MMR defects, whereas instability only in dinucleotides is characteristic of MSI-L/MMR-positive tumors.
引用
收藏
页码:2180 / 2187
页数:8
相关论文
共 52 条
[1]  
Ahnen DJ, 1998, CANCER RES, V58, P1149
[2]  
Ashktorab H, 2003, CLIN CANCER RES, V9, P1112
[3]  
Bocker T, 1997, CANCER RES, V57, P4739
[4]  
Boland CR, 1998, CANCER RES, V58, P5248
[5]  
Bubb VJ, 1996, ONCOGENE, V12, P2641
[6]   Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer [J].
Carethers, JM ;
Smith, EJ ;
Behling, CA ;
Nguyen, L ;
Tajima, A ;
Doctolero, RT ;
Cabrera, BL ;
Goel, M ;
Arnold, CA ;
Miyai, K ;
Boland, CR .
GASTROENTEROLOGY, 2004, 126 (02) :394-401
[7]  
Chaves P, 2000, J PATHOL, V191, P355
[8]   The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas [J].
Cunningham, JM ;
Kim, CY ;
Christensen, ER ;
Tester, DJ ;
Parc, Y ;
Burgart, LJ ;
Halling, KC ;
McDonnell, SK ;
Schaid, DJ ;
Vockley, CW ;
Kubly, V ;
Nelson, H ;
Michels, VV ;
Thibodeau, SN .
AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 69 (04) :780-790
[9]   Replication error phenotype, clinicopathological variables, and patient outcome in Dukes' B stage II (T3,N0,M0) colorectal cancer [J].
Curran, B ;
Lenehan, K ;
Mulcahy, H ;
Tighe, O ;
Bennett, MA ;
Kay, EW ;
O'Donoghue, DP ;
Leader, M ;
Croke, DT .
GUT, 2000, 46 (02) :200-204
[10]   Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer [J].
de Jong, AE ;
van Puijenbroek, M ;
Hendriks, Y ;
Tops, C ;
Wijnen, J ;
Ausems, MGEM ;
Meijers-Heijboer, H ;
Wagner, A ;
van Os, TAM ;
Bröcker-Vriends, AHJT ;
Vasen, HFA ;
Morreau, H .
CLINICAL CANCER RESEARCH, 2004, 10 (03) :972-980